Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):289–296. doi: 10.1097/QAI.0000000000000968

Figure 3. Rilpivirine C24 during Pregnancy and Postpartum.

Figure 3

24 hour post-dose rilpivirine concentration during the second and third trimesters, and again postpartum. Each line represents a single subject. Dashed line represents subject on concomitant darunavir/ritonavir.

P=0.013 for second trimester versus postpartum with the Wilcoxon signed-rank test.

P=0.003 for third trimester versus postpartum with the Wilcoxon signed-rank test.

P=0.309 for second trimester versus third trimester with the Wilcoxon signed-rank test.